Cargando…

Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study

BACKGROUND: Transforming potentially resectable advanced esophageal squamous cell carcinoma (ESCC) into resectable ESCC through preoperative induction therapy is an important component of ESCC comprehensive treatment. Immune checkpoint inhibitor (ICI) therapy has been shown to have significant effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Pinghui, Li, Pan, Wu, Simeng, Wang, Yiqing, Ye, Peng, Zhang, Chong, Hu, Jian, Kidane, Biniam, Lampridis, Savvas, Velotta, Jeffrey B., Wakefield, Connor J., Zhu, Linhai, Wang, Luming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577786/
https://www.ncbi.nlm.nih.gov/pubmed/36267734
http://dx.doi.org/10.21037/atm-22-4268
_version_ 1784811837180608512
author Xia, Pinghui
Li, Pan
Wu, Simeng
Wang, Yiqing
Ye, Peng
Zhang, Chong
Hu, Jian
Kidane, Biniam
Lampridis, Savvas
Velotta, Jeffrey B.
Wakefield, Connor J.
Zhu, Linhai
Wang, Luming
author_facet Xia, Pinghui
Li, Pan
Wu, Simeng
Wang, Yiqing
Ye, Peng
Zhang, Chong
Hu, Jian
Kidane, Biniam
Lampridis, Savvas
Velotta, Jeffrey B.
Wakefield, Connor J.
Zhu, Linhai
Wang, Luming
author_sort Xia, Pinghui
collection PubMed
description BACKGROUND: Transforming potentially resectable advanced esophageal squamous cell carcinoma (ESCC) into resectable ESCC through preoperative induction therapy is an important component of ESCC comprehensive treatment. Immune checkpoint inhibitor (ICI) therapy has been shown to have significant effects in the treatment of advanced ESCC, but its role in the neoadjuvant treatment of potentially resectable ESCC is unclear. This study aims to investigate the safety and effectiveness of camrelizumab combined with chemotherapy in the neoadjuvant treatment of ESCC. METHODS: We recruited consecutive patients with potentially resectable ESCC who received preoperative camrelizumab in combination with chemotherapy. Data including demographic data, clinicopathological characteristics, neoadjuvant treatment regimens, lesion changes observed by imaging, and surgical details were retrospectively collected through specially designed forms. Toxic effects of neoadjuvant therapy on hematology, gastrointestinal tract, liver, kidney, skin, and thyroid were also collected. Imaging assessments were performed every 1–2 treatment cycles. Follow-up is based on the patient’s regular admission to the hospital for examination and treatment, at least 3 months after surgery. RESULTS: A total of 66 patients with locally advanced ESCC were included in this study, including 8 patients with stage II, 29 patients with stage III, and 29 patients with stage IVA. The objective response rate (ORR) of the neoadjuvant immunotherapy combined with chemotherapy was 75.76% (50/66), and no one developed disease progression. A total of 60 patients underwent surgery, and the R0 resection rate was 98.3% (59/60). The pathological complete remission (pCR) rate and the major pathological response (MPR) rate was 6.7% (4/60) and 20% (12/60), respectively. There were 14 cases of treatment-related adverse reactions >3, but no perioperative deaths occurred. CONCLUSIONS: Neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection may be an available treatment for patients with locally advanced ESCC.
format Online
Article
Text
id pubmed-9577786
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-95777862022-10-19 Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study Xia, Pinghui Li, Pan Wu, Simeng Wang, Yiqing Ye, Peng Zhang, Chong Hu, Jian Kidane, Biniam Lampridis, Savvas Velotta, Jeffrey B. Wakefield, Connor J. Zhu, Linhai Wang, Luming Ann Transl Med Original Article BACKGROUND: Transforming potentially resectable advanced esophageal squamous cell carcinoma (ESCC) into resectable ESCC through preoperative induction therapy is an important component of ESCC comprehensive treatment. Immune checkpoint inhibitor (ICI) therapy has been shown to have significant effects in the treatment of advanced ESCC, but its role in the neoadjuvant treatment of potentially resectable ESCC is unclear. This study aims to investigate the safety and effectiveness of camrelizumab combined with chemotherapy in the neoadjuvant treatment of ESCC. METHODS: We recruited consecutive patients with potentially resectable ESCC who received preoperative camrelizumab in combination with chemotherapy. Data including demographic data, clinicopathological characteristics, neoadjuvant treatment regimens, lesion changes observed by imaging, and surgical details were retrospectively collected through specially designed forms. Toxic effects of neoadjuvant therapy on hematology, gastrointestinal tract, liver, kidney, skin, and thyroid were also collected. Imaging assessments were performed every 1–2 treatment cycles. Follow-up is based on the patient’s regular admission to the hospital for examination and treatment, at least 3 months after surgery. RESULTS: A total of 66 patients with locally advanced ESCC were included in this study, including 8 patients with stage II, 29 patients with stage III, and 29 patients with stage IVA. The objective response rate (ORR) of the neoadjuvant immunotherapy combined with chemotherapy was 75.76% (50/66), and no one developed disease progression. A total of 60 patients underwent surgery, and the R0 resection rate was 98.3% (59/60). The pathological complete remission (pCR) rate and the major pathological response (MPR) rate was 6.7% (4/60) and 20% (12/60), respectively. There were 14 cases of treatment-related adverse reactions >3, but no perioperative deaths occurred. CONCLUSIONS: Neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection may be an available treatment for patients with locally advanced ESCC. AME Publishing Company 2022-09 /pmc/articles/PMC9577786/ /pubmed/36267734 http://dx.doi.org/10.21037/atm-22-4268 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Xia, Pinghui
Li, Pan
Wu, Simeng
Wang, Yiqing
Ye, Peng
Zhang, Chong
Hu, Jian
Kidane, Biniam
Lampridis, Savvas
Velotta, Jeffrey B.
Wakefield, Connor J.
Zhu, Linhai
Wang, Luming
Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study
title Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study
title_full Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study
title_fullStr Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study
title_full_unstemmed Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study
title_short Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study
title_sort evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577786/
https://www.ncbi.nlm.nih.gov/pubmed/36267734
http://dx.doi.org/10.21037/atm-22-4268
work_keys_str_mv AT xiapinghui evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy
AT lipan evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy
AT wusimeng evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy
AT wangyiqing evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy
AT yepeng evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy
AT zhangchong evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy
AT hujian evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy
AT kidanebiniam evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy
AT lampridissavvas evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy
AT velottajeffreyb evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy
AT wakefieldconnorj evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy
AT zhulinhai evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy
AT wangluming evaluationofthesafetyandeffectivenessofneoadjuvantcombinedchemoimmunotherapyinthetreatmentoflocallyadvancedesophagealsquamouscellcarcinomaaretrospectivesinglearmcohortstudy